chrisvoncsefalvay/vaers-outcomes huggingface dataset:
numbness in her left hand and arm; This case was reported by a nurse via call center representative and described the occurrence of numbness in hand in a 24-year-old female patient who received Rabies NVS (RabAvert) (batch number ARBA241A, expiry date 20th July 2022) for prophylaxis.   On 13th November 2019, the patient received RabAvert. On 13th November 2019, less than a day after receiving RabAvert, the patient experienced numbness in hand. The patient was treated with steroids nos (Steroids) and analgesic, nos (Analgesic). On an unknown date, the outcome of the numbness in hand was recovering/resolving.   It was unknown if the reporter considered the numbness in hand to be related to RabAvert.  Additional details were received as follows: The reporter stated that the patient started experiencing numbness in her left hand and arm following a dose of Rabavert. The healthcare professional describes numbness as feeling like the arm has fallen asleep. The healthcare professional noted the has full sensation during this experience. Patient was seen by the Doctor and the Doctor would be prescribing a steroid dose pack and mild analgesic. No exact start time of numbness provided. The numbness was beginning to improve at the time of the time of reporting. No additional information provided. The reporter consented to follow up.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 55-year-old female patient received BNT162b2 (BNT162B2), as dose 4 (booster), single (Batch/Lot number: unknown), in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "RA" (unspecified if ongoing); "diabetes" (unspecified if ongoing); "Anemia" (unspecified if ongoing); "GI" (unspecified if ongoing); "IBS" (unspecified if ongoing); "SIBO" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Jun2022, outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical course: Patient received treatment of Paxlovid started on 29JUN2022 and stopped on 04JUL2022 and had event of awful bitter taste in mouth all day long (bitter grapefruit and soap).  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Patient verified completed consent form with pharmacist before vaccine administration. Staff Pharmacist informed him of EUA and V-safe program and about vaccine card for patient to keep, and reviewed most common side effects and common treatment options. Vaccine administered around 2:45pm August 18th, 2021. Staff Pharmacist asked patient to wait 15 minutes after vaccine before leaving and returned to pharmacy after verbal confirmation from patient. Patient later found sitting in foyer of store by store manager. Pharmacist brought chocolate bar and water offered (both cold and room temperature). Patient also called mother after he vomited. Pieced together: patient says he was stepping out to car for a moment for something and on the way (around 2:50pm) patient started feeling bad and when he 'came-to' he was sitting on the floor in the store foyer. He then felt sick and vomited into trashcan (per store manager) and called mother. Mother arrived after pharmacist offered water and chocolate and asked for icepack to cool patient, which store manager went to get. Per patient, he ate before hand, was not tired or feeling poorly before or during vaccine. Pharmacist asked patient how he felt, and he stated he was feeling better and visually store manager said color was returning to his face. Mother stated patient has never fainted from a vaccine before, but he does have a history (similar to mother) of "fainting when he gets sick or feels bad." She asked if he waited 15 minutes before leaving pharmacy and patient stated pharmacist did ask him to stay but he wanted to go to his car briefly and planned to return to waiting area. Patient sat on chair in foyer about 20 minutes before stating he felt fine and wanted to leave.  Pharmacist asked patient to "let any healthcare personnel know for the future" regarding his fainting history. Mother stated it's likely patient worked himself up regarding getting this vaccine which then resulted in fainting episode.
Local Rxn w/ redness & warmth x 40 hours:  then pain in arm radiating to shoulder/neck & elbow -> referred to physical therapy on 4-3-09.
Pain in the bones; A sore throat; This spontaneous case was reported by a consumer and describes the occurrence of BONE PAIN (Pain in the bones) and OROPHARYNGEAL PAIN (A sore throat) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 010A21A and 007M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 14-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 31-Mar-2021, the patient experienced BONE PAIN (Pain in the bones) and OROPHARYNGEAL PAIN (A sore throat). At the time of the report, BONE PAIN (Pain in the bones) and OROPHARYNGEAL PAIN (A sore throat) outcome was unknown. Not Provided          No concomitant medications were provided. Treatment medications were unknown. Action taken with mRNA-1273 in response to the events was not applicable.  The patient has already received both doses and wants to know if she can get the vaccine again in 6 months.
Mother called to report brother had generalized rash 01/07/04.  Note this infant had (20-30) macular areas on back and abdomen.  Advised mother to treat as needed for fever and pruritis and consider MD appointment.  No ASA.
Less than 24 hour after Menactra fever, chills, GI upset, malaise instructed to treat symptomatically if worsens or rash, hives to emergency room.
Post vax, on 08/01/2001 the patient started with a fever of 103F. The patient was treated with Advil. The patient also had a headache and congestion. On 08/03/2001 the patient had swollen feet and a rash. The patient was referred to a MD. The next day the rash was gone and the child was OK.
< 1 hr post vaccine admin. Pt c/o lightheaded, loss of appetite, nausea, cold chills, unable to move feet.  C/o vision change. 1 hour later pt c/o headache & stomach pain. C/o weakness. Difficulty ambulating.  & irregular heartbeat & palpitations.  3/16/09 Received PCP medical records of 1/28-2/19/2009. FINAL DX: anxiety, sinus tachycardia resolved. Records reveal patient experienced epigastric pain c/w PUD.  Tx w/meds.  RTC 2/18 & epigastric pain had resolved until day prior when returned but much milder.  To continued meds x 2 mo than return for recheck.  Seen in ER on 2/19 for SOB, tachycardia.  Exam at that time was WNL & d/c to home.
Joint pain in both knees that was never present before. It hurts to stand up and sometimes just sitting, never related to activity.; This is a spontaneous report from a non-contactable consumer, the patient. A 30-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the left arm on 06Apr2021 at 10:00 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. The patient had no known allergies. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any concomitant medications. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 07Apr2021, the patient experienced joint pain in both knees that was never present before. The patient reported that it hurt to stand up and sometimes just sitting, never related to activity. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event joint pain in both knees that was never present before was not resolved at the time of this report.   No follow-up attempts are possible. No further information is expected.
Information has been received from a physician referring to a 4 months old female patient with milk protein allergy, poor weight gain and reflux. The patient did not have drug reactions/allergies. On 02-OCT-2015, the patient was vaccinated with the first dose of ROTATEQ (lot #, expiration date and dose unspecified) orally as "age appropriate vaccine" and there was no adverse effect reported. On 03-DEC-2015 the patient received the second dose of ROTATEQ (lot # unspecified, expiration date 02-NOV-2016, 2ml) orally. There was no concomitant medication taken. On an unspecified date in December 2015, the patient developed blood and mucus in the stools. The patient's mother had sought medical attention by calling the office. No treatment was given for the events. None lab diagnostics studies was performed. The outcome of the events was reported as not recovered. Causality was not provided. The physician considered the adverse events to be significant disability or incapacity because it would cause decreased growth and poor weight gain in the patient. Additional information has been requested.
Bruising, slight redness. Reviewed normal course, resolution and complication after vaccine, advised patient to increase movement of arm, and to use ice as needed, if not better patient would return back.
Right upper arm radiating from injection site with redness, warmth, and firmness. Started 1/12/21 and worsened in size and warmth on 1/13/21. Sought medical care on 1/14/21 - area was slightly improved at that time. Medical provider felt that this was a localized reaction and treated with ice and NSAIDS. Area improved over the next few days until resolved.
MMR Vaccine gave me bad reaction.; This spontaneous report was received from a health professional via other company, referring to a 58-year-old female patient.  The patient's concurrent conditions, medical history and concomitant therapies were not reported.  On unknown dates, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (strength, dose, frequency, route of administration, anatomical location, lot # and expiration date were not reported) as prophylaxis; with influenza virus vaccine (unspecified), and with tuberculin purified protein derivative (reported as PPD) vaccine (strengths, doses, frequencies, routes of administration, anatomical locations, lot # and expiration dates were not reported) as prophylaxis.  On an unspecified date, the measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) gave her a bad reaction (vaccination complication). The tuberculin purified protein derivative (PPD) vaccine caused her a skin reaction of 40 millimeters ''very huge''; and the influenza virus vaccine (unspecified) gave her ''Malesia'' syndrome and she lost 16 pounds. At the reporting time, the outcome of vaccination complication was not provided.  On unspecified dates between 2020 or 2021, the patient was vaccinated with the first dose of SARS-CoV-2 spike protein mRNA vaccine (reported as PFIZER-BIONTECH COVID-19 VACCINE). On 04-MAR-2021, the patient had severe side effects of vaccine including seizure disorder and right arm swelling. Her husband brought her to the hospital, and she was admitted. After that, she was very scary, very wild and screaming, her memory was gone. On an unspecified date (reported as today), the patient was scheduled for second dose of the vaccine, but she was scared to go, as it affected her mental status.   The causal relationship between vaccination complication and measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) was related.
Adverse Event: Injection site pain. Fever 101 oral, Body Ache and headache on 2/11/21.  Treatment: Tylenol, Tramadol and rest.  Outcome: Fever resolved on 2/12/21
received the fluzone flu shot at 9 am, by 9:10, started getting hot in area and red. By 9:25 started itching and then arm started swelling. Tried to relieve with ice, didn't help. Then got dizzy and hot and nauseated. Went down to RN who administered shot and she called employee health and I saw a PA at 10:10. She said this is a common side effect and prescribed ibuprofen and benadaryl. Took 1/2 a tablet at 10:45 of Benadryl and within 20 minutes symptoms were relieved and then arm started hurting. No other symptoms occurred the rest of the day besides sore arm.
I was at home my head was hurting I was hot and kept drinking water and took ibuprofen and my temp got to 105. The ambulance took me to hospital. They said they couldn't do anything till my fever went down which took 3 hours. They told me to follow up with my PCP. Days later I yellow pimples all over my body. My head frying and my eyeballs, and I couldn't be cooled down. I don't remember what happened after that. My chest and head was hurting and it took a long time to recover. ER told me I had an allergic reaction to the vaccine. My head still hurts and my eye vision has changed and my heart rate has been fast paced still.
Patient states she went to a mass vaccination clinic site. Reports after getting the first dose of the Moderna  vaccine she developed full body diaphorisis, flushing, blurry vision,  and LOC within ~30min. Furthermore, when she regained consciousness in  the ambulance she developed rigors, hives, and angioedema. She was  taken to a local ER and stabilized at the site. She was discharged same  day in stable condition with prescriptions to fill for an EPI-Pen, OTC  Tylenol, OTC Benadryl.
Experienced nausea , vomiting  & diarrhea 15 minutes after receiving vaccine (2nd COVID shot), no dizziness or SOB, Vital signs stable. pt observed for an hour and with no improvement of symptoms (had another episode of diarrhea.). EMS called and pt taken to ED for evaluation. Reporter not know outcome of ED visit.
Provider Summary "78-year-old female with history of HFrEF, dm 2, CKD 3, HLD, coronary artery disease with history of MI and CABG in 2019, PAF on Eliquis admitted for sepsis found to be secondary to COVID pneumonia as well as urinary tract infection.  Sepsis quickly resolved and patient found to have ESBL E coli for which patient received full 3 day course of ertapenem.  Patient did have some encephalopathy on admission which resolved likely secondary to urinary tract infection. Patient however treated for hypoxia with steroids and remdesivir in by time of discharge had been weaned off of supplemental oxygen (2 L) back to her baseline of room air for least 24 hours prior to discharge.  Noted the patient did have worsening creatinine up to 1.9 (baseline 1.6) during hospitalization for which patient's home Bumex had been temporarily held although restarted as could be cardiorenal as patient was developing 1 to 2+ edema half way up to the knees bilaterally.  Patient discharged with 3 more days of dexamethasone to complete 10 day course and continue on Tessalon although patient's cough much improved by time of discharge.  No other changes made to patient's medications."
pc from mom 8JUL93 pt recvd vax 23JUN93 sick since fever & swollen glands 2 days p/shot; rash all over head to toe; feels OK now just itches;
This case was reported by a consumer via interactive digital media and described the occurrence of cancer in a patient who received BOOSTRIX for prophylaxis. On an unknown date, the patient received BOOSTRIX. On an unknown date, 2 years after receiving BOOSTRIX, the patient experienced cancer (serious criteria GSK medically significant), guillain barre syndrome (serious criteria GSK medically significant), leukemia (serious criteria GSK medically significant), anemia, joint pain, bone pain, back pain and performance status decreased. On an unknown date, the outcome of the cancer, guillain barre syndrome, leukemia, anemia, joint pain, bone pain, back pain and performance status decreased were unknown. It was unknown if the reporter considered the cancer, guillain barre syndrome, leukemia, anemia, joint pain, bone pain, back pain and performance status decreased to be related to BOOSTRIX. Additional details were provided as follows: The age at vaccination was not reported. Two years after receiving BOOSTRIX, the patient experienced leukemia symptoms. 11.5 years passed, could not function properly. The patient was going to hematologist in further week to confirm the diagnosis. The patient wanted to know how can he or she sue GlaxoSmithKline for the vaccine causing guillain barre syndrome, anemia, bone, back, joint pains and cancer.
1. Bad headache 2. Pain in teeth (like nerves) that went away. 3. Extreme fatigue/chronic fatigue. The symptoms continue. I experienced a very bad debilitating headache that feels like it is behind my forehead. Fatigue. Today is day nine and I have not left my apartment. It's a little scary not knowing when this will go away. I'm now afraid to get the second shot.
All started the morning of the day after the vaccine shot and  got progressively got worse the entire day.  They were all gone by the next day.  Fatigue Nausea  Muscle Aches Confusion/dizziness
30 minutes after vaccination, client felt her cheeks feel "squishy", right greater than left.  Face did not look abnormal to nurse.  Client preferred to sit, instead of lying down on cot.  Client stated she has had this feeling in the past with other allergic reactions (seasonal). Also history of anaphalactic reaction to wine many years ago.  Client had her own Benadryl with her and self administered 50mg of liquid gels.  Bit and swallowed the liquid.  BP 130/92, HR 68, O2 Sat 98 at the time of taking Benadryl.  Skin was dry and flushed.  Alert and conversing with nurse.  After 5 min, squishy feeling was residing, BP 134/92, HR 63, O2 Sat 97.  Alert and conversing.   15 minutes after taking Benedryl, feeling almost gone and client wanted to leave.  VSS, coloring pink and skin dry.  Advised to seek care at ER if feeling returns or call 911.  Client agreed.  Walked out of building by herself.
Weird rash; Red and patchy at the area she received the vaccine; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE RASH (Weird rash) and VACCINATION SITE ERYTHEMA (Red and patchy at the area she received the vaccine) in a 22-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002A21A) for COVID-19 vaccination.     Concomitant products included PAROXETINE for an unknown indication.    On 26-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE RASH (Weird rash) and VACCINATION SITE ERYTHEMA (Red and patchy at the area she received the vaccine). At the time of the report, VACCINATION SITE RASH (Weird rash) and VACCINATION SITE ERYTHEMA (Red and patchy at the area she received the vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Child exposed to friend with shingles and developed a rash. Approximately 50 small blisters with red base on arms and trunk at time of visit in the office with more areas appearing.
This spontaneous report was received from a registered nurse and refers to a patient of unknown age and gender. There was no information about patient's pertinent medical history, concomitant medications, drug reactions or allergies provided. On 20-MAY-2013, the patient was vaccinated with the first dose of GARDASIL (lot # H020692, expiration date 15-AUG-2015, dose, anatomical loction and route of administration were not reported). On 28-JUN-2013, the patient was vaccinated with the second dose of GARDASIL (lot # J004770, expiration date 27-NOV-2015, dose, anatomical location and route of administration were not reported). On 27-NOV-2013, the patient was vaccinated with the third dose of GARDASIL (lot # J009993, expiration date 04-DEC-2015), dose, anatomical location and route of administration were not reported). On 29-JAN-2015, the patient received the fourth dose of GARDASIL 9) (lot # L019297, expiration date 08-AUG-2017), dose, anatomical location and route of administration were not reported). No adverse events were reported. Additional information has been requested.
Within 15 minutes of receiving Hep-B injection, started feeling dizzy, hot flashes and chills. Feeling of lump in throat and also stated had a headache.
Slight soreness at injection area on day 2; ended by day 3. On the evening of day 6, area was itchy, red, swollen, sore, and warm to the touch. The swelling was 4" in diameter and raised about 3/4 - 1 inch.  n
Pt. received PROQUAD (varicella and MMR) vaccination on 2.1.16 at 15 month well child exam. While on office on 2.25.15 a shingles rash was noted to left lower back. Rash was noticed by mother 7 days after injected. To right outer thigh. Approx. 7 days later mother noticed rash to left lower back. Pt in office on 2.25.16 for ear infection when dr. noted lesions on left lower back.
Patient reported to pharmacy on 11/3/14 c/o shingles-type lesion (blisters, swelling, and heat, approximately 13cm in diameter), fever reported by patient of 102.4 degrees Fahrenheit beginning the morning after vaccination with Zostavax. Patient to report to urgent care clinic of primary care clinic today, 11/4/14.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A female patient (not pregnant) received BNT162b2 (BNT162B2), on 09Jun2021 as dose 1, single (Lot number: ew0186), on 13Aug2021 as dose 2, single (Lot number: ew0191), in right arm and on 04Mar2022 as dose 3 (booster), single (Lot number: fm0698), in right arm for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (18Jul2022) Positive, notes: Tested Positive at home 18Jul2022; (26Jul2022) Negative, notes: Tested Negative at home 26Jul2022; (30Jul2022) Positive, notes: Tested Positive at home 30Jul2022.Therapeutic measures were taken as a result of vaccination failure, covid-19 which included treatment with Paxlovid treatment start date was 18Jul2022 and stop date was 22Jul2022.  Clinical course: Patient vaccine received and no any Other medications in two weeks. No Known allergies  No follow-up attempts are possible. No further information is expected.
within 15 minutes observation period developed pain in right arm followed by numbness of right arm, and pain behind right eye.  BP 160/94, repeat 140/83, HR 83, O2 sat 100%.  worsening over 30 minutes.  So code assist called and taken to ED. allergist on duty provided consultation and follow-up, confirming symptoms resolved same day.